RWJBarnabas Health and Rutgers Cancer Institute of New Jersey | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Latest from RWJBarnabas Health and Rutgers Cancer Institute of New Jersey

Researchers Find Tumor Microbiome Interactions May Identify New Approaches for Pancreatic Cancer Treatment

October 17, 2022

Article

Investigators from Rutgers Cancer Institute of New Jersey examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival.

Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New Jersey

October 10, 2022

Article

Further enhancing its focus on providing outstanding, innovative and compassionate care for cancer patients, Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, are welcoming a new leader to its team of internationally recognized physicians and researchers.

New Chief of Blood Disorders Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

September 15, 2022

Article

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, MD, MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal Cancer

September 04, 2022

Article

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

Exploring Cancer and Health Data on Asian American and Pacific Islanders

August 30, 2022

Article

Antoinette Stroup, PhD, shares personal and professional insight on the disaggregation of cancer health statistics regarding the Asian American and Pacific Islander community.

Unraveling of Genetic Mechanism Behind Tumor Formation May Improve Targeted Treatment for Cancer Patients

August 17, 2022

Article

Addressing the Unique Needs of LGBTQ+ Cancer Patients

August 12, 2022

Article

Joan Hogan, DSW, LCSW, OSW-C, and Rosemarie Slirzewski, MSW, LCSW, expand on the unique needs and challenges of LGBTQ+ individuals who are faced with cancer.

Rutgers Cancer Institute of New Jersey Receives State’s Highest Score in Cancer Specialty

August 10, 2022

Article

Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, has been recognized as one of the top five hospitals in New Jersey and a top 20 Regional Best Hospital in the New York Metropolitan area by U.S. News & World Report in the annual Best Hospitals rankings.

Enhancing Awareness and Participation of Black Breast Cancer Patients in Clinical Trials

August 01, 2022

Article

Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.

Rutgers Cancer Institute of New Jersey and its Top Research Leader Dr. Eileen White Selected to Lead Global Cancer Grand Challenges Team Taking on Cancer Cachexia

July 13, 2022

Article

A world-class team of researchers assembled and led by Rutgers Cancer Institute of New Jersey and its Deputy Director and Chief Scientific Officer Eileen White, PhD, has been awarded a $25 million Cancer Grand Challenges grant to tackle the condition of cancer cachexia.

Rutgers Cancer Institute Research Leader Eileen White Named Rutgers Board of Governors Professor of Molecular Biology and Biochemistry

July 08, 2022

Article

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.

ANCHOR Study Shows Treatment of Precancerous Lesions in Individuals Living With HIV Reduces Anal Cancer Risk by Half

July 05, 2022

Article

Results from a study of individuals living with HIV show treatment of a precancerous condition known high-grade squamous intraepithelial lesions of the anus cuts the risk of developing anal cancer in this population by more than half.

Radiation Therapy as Effective as Surgery for Prostate Cancer

June 30, 2022

Article

Ronald D. Ennis, MD, shares how radiotherapy is an excellent treatment for many men with prostate cancer, providing a minimally-invasive treatment with low adverse effect risks.

Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 19, 2022

Video

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. George on the Background of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 16, 2022

Video

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients

June 16, 2022

Article

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.

New Chief of Bone Marrow Transplant and Cellular Therapies Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

June 08, 2022

Article

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital.

Dr. Goel on the Need for Diverse Representation in Clinical Trials

May 26, 2022

Video

Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.

Addressing Barriers Contributing to Disparities in CRC Screening in Underserved Populations

May 20, 2022

Article

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

Dr. O'Malley on Racial and Economic Barriers to Screening in CRC

May 13, 2022

Video

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.